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Abstract 
 
The neurodegenerative disease Autosomal Recessive Spastic Ataxia of Charlevoix Saguenay 
(ARSACS) is caused by loss of function of sacsin, a modular protein that is required for normal 
mitochondrial network organisation. 
 
To further understand cellular consequences of loss of sacsin we performed microarray analyses 
in sacsin knockdown cells and ARSACS patient fibroblasts. This identified altered transcript levels 
for oxidative phosphorylation and oxidative stress genes. These changes in mitochondrial gene 
networks were validated by quantitative reverse transcription PCR. Functional impairment of 
oxidative phosphorylation was then demonstrated by comparison of mitochondria bioenergetics 
through extracellular flux analyses. Moreover, staining with the mitochondrial specific fluorescent 
probe MitoSox suggested increased levels of superoxide in patient cells with reduced levels of 
sacsin. 
 
Key to maintaining mitochondrial health is mitochondrial fission, which facilitates the dynamic 
exchange of mitochondrial components and separates damaged parts of the mitochondrial network 
for selective elimination by mitophagy. Fission is dependent on Dynamin related protein 1 (Drp1), 
which is recruited to prospective sites of division where it mediates scission. In sacsin knockdown 
cells and ARSACS fibroblasts, we observed a decreased incidence of mitochondrial associated 
Drp1 foci. This phenotype persists even when fission is induced by drug treatment. Mitochondrial 
associated Drp1 foci are also smaller in sacsin knockdown cells and ARSACS fibroblasts. 
 
These data suggest a model for ARSACS where neurons with reduced levels of sacsin are 
compromised in their ability to recruit or retain Drp1 at the mitochondrial membrane leading to a 
decline in mitochondrial health, potentially through impaired mitochondrial quality control. 
 
  
 3 
Introduction 
 
The neurodegenerative disease Autosomal Recessive Spastic Ataxia of Charlevoix Saguenay 
(ARSACS: OMIN 270550) was originally identified in Quebec, but is now known to have a 
worldwide distribution (1, 2). ARSACS is regarded as the second most common recessive ataxia 
and typically presents with a prominent cerebellar ataxia, spasticity, and peripheral neuropathy. 
Central to ARSACS pathology is Purkinje cell loss, which has been documented from patient brain 
and observed in a mouse model of the disease (3-5). 
 
ARSACS is caused by mutations in the SACS gene that encodes sacsin/DNAJC29 (1). At 4579 
amino acids in length sacsin is one of the largest proteins encoded by the human genome. It is a 
modular protein that from N- to C-terminus is composed of a ubiquitin-like (UBL) domain that binds 
to the proteasome (6), three large sacsin repeat regions (SRR) that may have an Hsp90-like 
chaperone function (7), a J-domain that binds Hsp70 (6, 8) and a higher eukaryotes and 
prokaryotes nucleotide-binding (HEPN) domain that can dimerise (6-10). Despite the identification 
of these domains sacsin’s cellular role is unknown. 
 
We have previously reported that siRNA mediated knockdown of sacsin leads to a reduction in 
mitochondrial membrane potential and a more interconnected mitochondrial network in the SH-
SY5Y neuroblastoma cell line (3). Mitochondrial membrane potential was also reduced in Purkinje 
neurons from sacsin knockout mice (3). Subsequently, it has been shown that mitochondria are 
elongated and have reduced mobility in motor neuron cultures from these KO mice (4), while, in 
cultured rat hippocampal neurons transduced with lentivirus encoding shRNAmiRs targeting 
sacsin, mitochondria are clustered and accumulate in the soma and proximal dendrites (3). 
 
There is increasing evidence that perturbation of the equilibrium between mitochondrial fission and 
fusion underlies mitochondrial defects that contribute to age-related neurodegenerative diseases, 
including Alzheimer's and Parkinson's (11, 12). This is because mitochondrial dynamics are 
essential for distribution, traffic and quality control of mitochondria. For mitochondrial quality control 
fission is required to sequester damaged parts of mitochondrial networks away from healthy 
mitochondria, acting as a precursor to their degradation by mitophagy (13). Importantly, deficits in 
mitochondrial fission may be particularly detrimental in neurons as they have bioenergetic 
demands at sites distant from the cell body requiring that they generate mitochondria of the correct 
size for transport along dendrites and axons. There is also the possibility that mitochondrial 
turnover may be restricted to the cell body, as opposed to occurring in axons (14), further linking 
mitochondrial dynamics and traffic to mitophagy. Moreover, mitochondrial dynamics facilitates the 
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exchange of mitochondrial matrix and membrane components between individual mitochondrion 
as part of mitochondrial network maintenance. 
 
As mitochondrial quality control mechanisms are intrinsically linked to mitochondrial division, 
disruption of fission has potential downstream consequences for important aspects of 
mitochondrial function. These include impaired oxidative phosphorylation. Unhealthy mitochondria 
are also likely to accumulate reactive oxygen species (ROS) and other markers of damage. 
Moreover, there is evidence of reduced mitochondrial fitness in multiple neurodegenerative 
diseases. For example, in Parkinson’s, a disease where the mitochondrial quality control 
machinery is compromised, respiration is impaired while ROS and antioxidant enzymes increase 
(15, 16). Evidence supporting impaired bioenergetics in Parkinson’s includes that fibroblasts from 
patients with sporadic disease show a significant decrease in respiration compared to controls 
(17).  
 
The mechanism through which loss of sacsin impairs mitochondrial function, distribution and 
network organisation is unclear, but could potentially be explained by either an increase in 
mitochondrial fusion or a decrease in fission. Supporting a model where loss of sacsin impairs 
fission we identified, through immunoprecipitation (IP), an interaction between the N-terminal 1368 
amino acids of sacsin (encompassing the UBL domain and first SRR) and the dynamin-related 
GTPase dynamin-related protein 1 (Drp1) (3). During mitochondrial fission Drp1 is recruited from 
the cytosol onto the outer mitochondrial membrane (OMM), where it assembles into foci. These 
foci consist of oligomeric Drp1 complexes that are thought to wrap around and constrict the 
mitochondrial tubule to mediate fission (18). 
 
In this study we used unbiased microarray and gene ontology analyses to identify oxidative 
phosphorylation and oxidative stress pathways as altered in sacsin knockdown cells and ARSACS 
patient fibroblasts. Changes in transcript levels for genes in these pathways were confirmed by 
quantitative reverse transcription PCR (RT-qPCR) in both sacsin knockdown cells and ARSACS 
patient fibroblasts. Bioenergetics profiles for cells lacking sacsin and accumulation of ROS were 
also analysed. Using siRNA mediated knockdown and ARSACS patient fibroblast cell lines we also 
examined the effect of reduced cellular levels of sacsin on Drp1 mitochondrial localisation. We 
identified a reduction in Drp1 foci at mitochondria and reduced translocation of Drp1 to 
mitochondria after ablation of mitochondrial membrane potential. This suggests sacsin may play a 
role in recruitment or retention of Drp1 at mitochondrial fission sites, with loss of this function 
leading to impaired mitochondrial health. 
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Results 
 
Microarray analyses implicate altered mitochondrial function in ARSACS 
To elucidate pathogenic mechanisms of ARSACS we performed two microarray experiments using 
a human Illumina Whole Genome Gene Expression BeadChip (HT-12 v4.0). We compared 
transcript levels in SH-SY5Y cells transfected with siRNAs targeting sacsin and control siRNAs 
(Figure S1), while in a complimentary experiment, gene expression profiling was performed to 
compare ARSACS patient and control human dermal fibroblasts (HDFs). For this part of the study 
four ARSACS HDF lines and two control HDF lines were used. ARSACS HDFS were from three 
compound heterozygous patients (c.2094-2A>G/Q4054*; K1715*/R4331Q; R2002fs/Q4054*) and 
one homozygous patient (2801delQ). Immunoblotting of lysates from these ARSACS HDF lines 
was performed using a commercially available antibody against an undefined sequence between 
residues 4100 and 4200 of sacsin. This detected a sacsin band in cell homozygous for the single 
amino acid deletion mutation 2801delQ, which was of similar intensity to that seen in WT control 
HDFs. In cells with the K1715*/R4331Q mutation a significantly fainter sacsin band was visible. 
This is consistent with the K1715*/R4331Q HDF line expressing detectable protein from a single 
allele. No sacsin was detected in the other two ARSACS HDF lines, although we could not 
preclude expression of a truncated protein (Figure S2). In sacsin knockdown cells 523 genes 
showed a significant change in expression levels, while in patient cells, expression of 572 genes 
was altered (p<0.05) (Figure 1A). Functional annotation clustering using the Database for 
Annotation, Visualization and Integrated Discovery (DAVID) (19), identified enrichment of genes in 
four clusters as common to the microarray comparing SH-SY5Y cells transfected with siRNAs 
targeting sacsin or scrambled siRNAs and the microarray comparing ARSACS and control HDFs 
(Figure 1B). Two of these clusters related directly to mitochondria with gene ontology terms 
including mitochondrial components, cell respiration, oxidative phosphorylation and oxidative 
stress. From the genes in these groupings we identified 18 genes where transcript levels showed a 
one fold or greater upregulation or down regulation in both the sacsin knockdown cells (Figure 1C) 
and ARSACS HDF cells (Figure 1D). These included 10 genes that function in oxidative 
phosphorylation (NDUFB3, NDUFB8, NDUFA9, NDUFB9, SDHD, UQCRFS1, COX7B, COX17, 
ATP5J and ATP5J2), 5 genes linked to oxidative stress (SOD2, MAFF, FOSB, FOS and ATF3) 
and 3 genes listed as mitochondrial components (SUCLA2, MTCH1 and HSPE1) (Figure 1D).  
 
Loss of sacsin function causes alterations in levels of oxidative phosphorylation and 
oxidative stress gene transcripts 
To validate alterations in transcript levels of oxidative phosphorylation and oxidative stress genes 
we used RT-qPCR. In an experiment that was independent from the microarray analyses, total 
RNA was extracted from sacsin knockdown and control SH-SY5Y cells. RT-qPCR was then 
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performed for each gene of interest with raw data normalised to GAPDH levels. In agreement with 
the microarray data we observed that expression of 8 oxidative phosphorylation genes were 
significantly decreased in cells with reduced levels of sacsin (Figure 2A). This included genes in 
each mitochondrial respiratory chain complex, with COX17 showing the greatest reduction in 
transcript levels (>35%). Contrastingly, 2 oxidative stress genes ATF3 and FOSB were slightly 
increased in sacsin knockdown cells, although these changes were not significant (Figure 2B). 
SOD2, which the microarray suggested was down regulated, was significantly upregulated in 
sacsin knockdown cells. Moreover, the mitochondrial component genes (SUCLA2 and MTCH1) 
that were identified as having reduced transcript levels in the microarray experiment were 
confirmed as being down regulated by RT-qPCR (Figure 2C). 
 
Total RNA was also extracted from the four ARSACS patient HDF cell line and five control HDF 
lines and RT-qPCR performed. Again we observed a down regulation of oxidative phosphorylation 
genes (Figure 2D), with 9 of the 10 genes identified from the microarray analyses exhibiting 
significantly decreased transcript levels in ARSACS HDFs (the exception was SDHD). As 
observed in the knockdown experiment COX17 was the oxidative phosphorylation gene that 
showed the greatest reduction in transcript levels (>60%). ARSACS HDFs also exhibited an 
upregulation of oxidative stress genes (Figure 2E) with SOD2, ATF3 and FOSB transcripts all 
significantly increased relative to controls. The most dramatic change was for FOSB, which 
showed a more than 150 fold increase in transcript levels. The mitochondrial component genes 
were also confirmed as down regulated in the patient cells (Figure 2F). With the exception of data 
for SOD2, changes in gene expression identified by the microarray and RT-qPCR experiments 
were in broad agreement. The combined data from analyses in sacsin knockdown cells and patient 
HDF demonstrates reduced expression of oxidative phosphorylation genes in cellular models of 
ARSACS and suggests oxidative stress is increased. 
 
Bioenergetic parameters are altered in sacsin knockdown and ARSACS patient cells. 
Bioenergetics profiling was performed to test for functional consequences of altered mitochondrial 
gene expression in cells lacking sacsin. Oxygen consumption rates (OCR) were measured in SH-
SY5Y cells that had previously been transfected with siRNAs targeting sacsin or control siRNAs 
(Figure 3A). Measurements were made under basal conditions and after sequential treatment with 
the ATP synthase (complex V) inhibitor oligomycin, followed by the uncoupling agent carbonyl 
cyanide-4 (trifluoromethoxy) phenylhydrazone (FCCP). OCR was then determined after 
mitochondrial respiration was shut down by combined treatment with the complex I inhibitor 
rotenone and the complex III inhibitor antimycin A. These analyses revealed that basal respiration, 
ATP production, proton leak, maximal respiration and spare capacity were all reduced in SH-SY5Y 
cells with reduced levels of sacsin, compared to controls (Figure 3A-B). These key parameters of 
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mitochondrial respiration where also compared in ARSACS patient HDF and control HDF lines. As 
observed in SH-SY5Y cells with reduced levels of sacsin, ARSACS patient HDF showed 
decreased OCR under basal conditions and after addition of mitochondrial inhibitors (Figure 3C-D). 
Both knockdown cells and HDFs showed a significant reduction in ATP coupled respiration and 
maximal respiration, strongly suggesting that compromised mitochondrial respiration is a feature of 
ARSACS. 
 
Increase levels of ROS in ARSACS patient cells. 
As gene expression analyses suggested increased oxidative stress in cells with reduced levels of 
sacsin we performed staining with MitoSOX Red to detect superoxide species. Confocal imaging of 
HDFs and subsequent measurement of fluorescent intensity revealed increased levels of MitoSOX 
staining in ARSACS patient cells relative to controls, this was confirmed by quantitative analyses of 
confocal images (Figure 4). We were unable to validate these findings in sacsin knockdown SH-
SY5Y cells, potentially because the transient knockdown did not reduce sacsin levels sufficiently, 
or for sufficient time, for ROS to accumulate (not shown). 
 
Localisation of Drp1 foci to mitochondria is reduced in sacsin knockdown cells. 
The gene expression and functional data presented here support that mitochondrial health is 
impaired in ARSACS. Potential mechanisms for this could include an increase in the proportion of 
defective mitochondria in sacsin null cells as a consequence of impaired mitochondrial dynamics 
and quality control. Moreover, ARSACS associated changes in mitochondrial network organisation 
are consistent with impaired Drp1 mediated mitochondrial fission (3). 
 
Based on these data we investigated mitochondrial recruitment of Drp1 in sacsin knockdown cells. 
Here we initially used control HDFs as they have a more distributed mitochondrial network that 
was better for quantitative imaging of Drp1 association. Cells were transfected with DSRed2-mito 
along with scrambled siRNAs or siRNAs targeting SACS. After 48 hours cells were fixed and 
stained for Drp1. Firstly, we confirmed that sacsin knockdown in HDFs impacted mitochondrial 
network organisation, observing that relative to control cells, sacsin knockdown HDFs frequently 
exhibited a hyperfused mitochondrial phenotype indicated by balloon-like or bulbed mitochondria 
(Figure S3). Interestingly, we also observed a larger total mitochondrial volume in individual cells 
transfected with SACS siRNAs relative to controls, suggesting increased mitochondrial mass in 
response to loss of sacsin (Figure S3). We then analysed the number of Drp1 foci localised on 
individual mitochondria (Figure 5A-B). We observed that for every 1µm along the length of a 
mitochondrion an average of 0.81±0.047 Drp1 foci occurred. This incidence of mitochondrial 
associated Drp1 foci was significantly reduced in sacsin knockdown HDFs where only 0.68±0.039 
foci localised per 1µm of mitochondrion. 
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We next tested if this observation reflected a reduction in the capacity of mitochondria in sacsin 
deficient cells to recruit Drp1 to prospective sites of fission (Figure 5A-B). To induce fission siRNA 
transfected cells were treated with carbonyl cyanide m-chlorophenyl hydrazine (CCCP), which 
abolishes membrane potential across the inner mitochondrial membrane leading to Drp1 
dependent fragmentation of mitochondria and ultimately mitophagy (20). Confocal imaging 
indicated extensive mitochondrial fragmentation after CCCP treatment in the cells transfected with 
the scrambled siRNA relative to cells where SACS was targeted (Figure 5A). The degree of 
mitochondria fragmentation was analysed by comparing the number of individual mitochondrion in 
cells treated with CCCP and vehicle controls. This confirmed that CCCP treatment resulted in 
higher levels of fragmentation of mitochondrial network in control HDFs than sacsin knockdown 
cells (Figure S3). Quantitative analyses identified that treatment with CCCP resulted in a significant 
increase in mitochondrial localized Drp1 foci in scrambled siRNA controls (p<0.0001). The number 
of Drp1 foci at mitochondria also increased in sacsin knockdown cells, but to a lesser degree than 
for the control (Figure 5B). Moreover, sacsin knockdown cells treated with CCCP still had less 
mitochondrial localised Drp1 foci than control cells that had not been treated to induce fission. This 
reduction in Drp1 recruitment was also confirmed in siRNA treated SH-SY5Y cells (Figure S4).  
 
As reduced cellular levels of sacsin impaired Drp1 recruitment to mitochondria we hypothesised 
the amount of Drp1 in individual foci may also be affected. To investigate this further we measured 
the diameter of individual cytosolic and mitochondrially localised Drp1 foci in control and sacsin 
knockdown cells (Figure 5C-D). In control cells we observed that cytosolic Drp1 foci were 
significantly smaller than those localised to mitochondria (p<0.0001), with respective diameters of 
0.38±0.0053µm and 0.52±0.0094µm. Comparison of the diameter of Drp1 foci between cells 
transfected with scrambled and SACS siRNA revealed that mitochondrial associated foci were 
16% smaller in cells lacking sacsin (p<0.0001). In contrast, there was no significant change in the 
size of cytosolic Drp1 foci between control and sacsin knockdown cells. We also measured the 
intensity of the Drp1 fluorescent signal for the mitochondrial associated Drp1 foci, observing this 
was also significantly reduced in sacsin knockdown cells relative to controls (p<0.01) (Figure 5E). 
To further confirm that Drp1 localisation to mitochondria was reduced upon sacsin knockdown we 
examined levels of the fission factor in mitochondrial fractions generated from SH-SY5Y cells. 
Immunoblot analyses of total cell lysates and mitochondrial fractions further supported reduced 
levels of mitochondrial associated Drp1 in cells with reduced levels of sacsin (Figure S4). 
 
A potential explanation for the reduction in mitochondrial associated Drp1 was that total levels of 
the fission factor are reduced in sacsin knockdown cells. Immunoblot analyses in SH-SY5Y 
suggested this was not the case, as sacsin knockdown did not significantly alter total Drp1 levels 
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(Figure 5F and Figure S4). However, when cells transfected with scrambled siRNAs and siRNAs 
targeting SACS were treated with a cross-linking agent before lysates were immunoblotted for 
Drp1 we observed a reduction in higher molecular weight Drp1 species in sacsin knockdown cells 
(Figure 5F-G). This may reflect an absence of Drp1:sacsin complexes, but could also indicate that 
Drp1 higher order oligomers, or complexes between Drp1 and other components of the fission 
machinery are reduced. 
 
Interestingly, as Drp1-mediated fission may precede removal of damaged mitochondria by 
mitophagy, we saw some evidence for decreased mitochondrial turnover in sacsin knockdown SH-
SY5Y cells. Using the mitochondrial matrix targeted fluorescent protein MitoTimer (21). We 
cotransfected a Tet-On SH-SY5Y cell line with pTRE-tight-MitoTimer and control siRNAs or 
siRNAs targeting SACS. 24 hours after transfection cells were treated with doxycycline for one 
hour to induce expression of the MitoTimer protein. A further 24 and 48 hours after this treatment 
cell were imaged and levels of fluorescence quantified. This showed a significant greater decrease 
in MitoTimer red fluorescence in control cells relative to sacsin knockdown cells (Figure S5).  
 
Localisation of Drp1 foci to mitochondria is reduced in ARSACS patient fibroblasts 
As a precursor to investigating Drp1 recruitment in ARSACS HDFs, we established that altered 
mitochondrial network morphology was a common feature of all ARSACS patient HDF lines 
investigated (Figure S6). This was accompanied by an increase in total mitochondrial volume per 
cell that was significant in two of the ARSACS HDF lines, but not overall (Figure S6). As in sacsin 
knockdown cells, we quantified the number of Drp1 foci localised on individual mitochondria in 
patient and control lines. This included a comparison of the number of Drp1 associated 
mitochondrial foci between vehicle treated cells and cells treated with CCCP to induce unopposed 
Drp1 recruitment (Figure 6A). We observed that for all the patient cell lines examined, significantly 
less Drp1 foci were localised to mitochondria than for control cells (Figure 6B and Figure S7). 
ARSACS patient cells also showed a reduced capacity to increase the number of mitochondrial-
associated foci after the induction of fission with CCCP. Mitochondrial associated Drp1 foci were 
also smaller with a reduced fluorescent intensity (when detected by immunofluorescent staining for 
Drp1), relative to controls (Figure 6C-D). 
 
In combination, our data in sacsin knockdown cells and ARSACS HDF lines, indicate that loss of 
sacsin impairs mitochondrial association of Drp1. 
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Discussion 
 
Data presented here support that decreased mitochondrial function is a feature of ARSACS. 
Specifically, we show that oxidative phosphorylation is impaired in cells lacking sacsin, including 
ARSACS patient HDFs. This is also consistent with decreased expression of nuclear genes 
encoding respiratory chain complex components and other mitochondrial proteins. These 
observations combined with an increase in expression of oxidative stress gene transcripts 
demonstrate that mitochondrial health is reduced in ARSACS. This is in agreement with another 
very recent study that has also reported reduced bioenegetic function and oxidative stress in 
ARSACS (22). This study compared five patient and control HDFs and did not corroborate findings 
in any cellular models with isogenic controls (this was a key reason we also performed 
comparative analyses in sacsin knockdown cells). 
 
Mitochondrial dynamics are disrupted in ARSACS, with our data showing that patient HDFs with a 
range of different ARSACS mutations have disrupted mitochondrial network organisation. This is 
consistent with the finding that recruitment of the fission protein Drp1 to the OMM is reduced in 
both SACS knockdown cells and ARSACS patient HDFs. As fission is integral to mitochondrial 
quality control we hypothesise that a failure to remove damaged mitochondria could explain the 
reduction in mitochondrial respiration and thus contribute to the molecular pathology of ARSACS. 
This idea is supported by our observation that mitochondrial turnover, measured by loss of 
MitoTimer fluorescence after a pulse of expression, is reduced in sacsin knockdown SH-SY5Y 
cells. In the context of this hypothesis it is important to consider known consequences of impaired 
Drp1 function. These include that complete loss of Drp1 is embryonic lethal in mice, with 
fibroblasts from these animals having elongated and more interconnected mitochondria (23, 24). In 
humans Drp1 also appears to be an essential protein as a mutation at a conserved residue 
(A359D) in the middle domain of Drp1 was neonatal lethal. In this case fibroblasts again exhibited 
a phenotype with mitochondrial elongation with tubular structures concentrated around the nucleus 
(25). Loss of sacsin is not embryonic lethal in mice or humans and Drp1 association with 
mitochondria is reduced rather than abolished in sacsin null cells. This less severe ARSACS 
phenotype signifies that sacsin is not essential for Drp1 mediated fission, but may be required for 
normal regulation of mitochondrial division in some cell types. 
 
This might be more similar to the phenotype in cells depleted for Fis1 and Mff (26). Targeting of 
these integral OMM proteins, that act as receptors to recruit Drp1 to the mitochondrial surface, 
were shown to result in increased mitochondrial interconnectivity with a reduction in the number 
and size of mitochondrial associated Drp1 foci. Despite phenotypic overlap, it seems unlikely that 
sacsin would function like Fis1 and Mff as a component of the Drp1 receptor machinery. This is 
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because sacsin is a cytosolic protein that localises at or near the OMM through an unknown 
mechanism. 
 
Another possible explanation for the decreased association of Drp1 to mitochondria in cells with 
less sacsin is impaired traffic of Drp1. Modulators of Drp1 distribution include the cytoplasmic 
dynein machinery, with over expression of the dynactin subunit, dynamitin (p50), altering 
mitochondrial dynamics and reducing the association of Drp1 with mitochondria (27). 
 
It also seems likely that cytoskeletal disorganisation more broadly contributes to the ARSACS 
mitochondrial phenotype. Loss of sacsin results in the accumulation of non-phosphorylated 
neurofilaments in vulnerable neuronal populations in SACS-/- mouse and ARSACS patient brain 
(4). Given that intermediate filaments, actin microfilaments and microtubules form an interlinked 
cytoskeletal network, it is likely that disruption of neurofilament organisation would impact directly 
on the distribution of mitochondria and plausibly influence Drp1 dynamics. Interestingly, 
connections between Drp1 mitochondrial association and cytoskeletal abnormalities have been 
established in animal models of Alzheimer’s disease and related tauopathies. Specifically, 
mitochondrial elongation as a consequence of Drp1 mislocalisation has been reported in 
Drosophila and mouse neurons expressing human tau, with evidence this is by a mechanism 
where phosphorylated tau excessively stabilises actin, inhibiting F-actin and myosin dependent 
translocation of Drp1 and mitochondria, with this contributing to mitochondrial dysfunction and cell 
death (28). 
 
It is interesting that patient HDFs have detectable cellular phenotypes yet ARSACS is purely a 
neurodegenerative disease. This supports the hypothesis that abnormal mitochondrial dynamics 
and function is particularly detrimental to neurons. Explanations of why neurons are highly 
sensitive to perturbations in mitochondrial dynamics include that they have energy requirements 
away from the cell body and must be able to traffic mitochondria relatively long distances (12). For 
ARSACS, impaired traffic is supported by the observation that mitochondrial motility was 
significantly reduced in axons of SACS−/− mouse motor neurons (4). Clues to potential mechanisms 
of Purkinje cell death, in response to impaired fission, come from studies using mouse postmitotic 
Purkinje cells depleted for Drp1. In these cells elongated mitochondria ultimately become swollen 
due to oxidative damage, losing respiratory function and accumulating markers of degradation. 
Moreover, treatment with antioxidants was shown to be neuroprotective (29). In addition to 
neurons being particularly vulnerable to aberrant mitochondrial dynamics, they are reported to 
have very limited glycolysis (30). Relative to some other cell types this makes neurons more highly 
dependent on aerobic oxidative phosphorylation, which our microarray and bioenergetics data 
indicates is impaired when sacsin function is lost. 
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Ultimately, it will be important to analyse the degree of mitochondrial dysfunction associated with 
ARSACS in neurons. It is encouraging that ARSACS HDFs have robust and quantifiable 
mitochondrial phenotypes, as this suggests that iPSC derived neurons generated from fibroblasts 
will be a useful and more disease relevant model. 
 
It has previously been found that oxidative phosphorylation complex assembly and function is 
modulated by mitochondrial dynamics, including Drp1 mediated fission (31). Moreover, gene 
expression studies have shown that levels of gene transcripts associated with oxidative 
phosphorylation, and other aspects of mitochondrial bioenergetics, are often reduced in 
neurodegenerative disease (32, 33). The expression of nuclear genes involved in mitochondrial 
function, including those encoding proteins required for oxidative phosphorylation, is controlled by 
mitochondria-to-nucleus signalling mechanisms. These in turn are modulated by factors such as 
calcium, ATP and ROS levels (34). It is thus likely that the changes in gene expression observed in 
response to loss of sacsin are a consequence of the altered mitochondrial dynamics either directly 
or more indirectly through factors such as the accumulation of ROS.  
 
Although we have shown reduced localisation of Drp1 to the OMM contributes to altered 
mitochondrial dynamics in ARSACS, the function of sacsin remains unclear. Based on sacsin’s 
repeating structure and large size, one possibility is that it may have a scaffold function. As sacsin 
has multiple domains that link to molecular chaperone and protein degradation systems it could 
potentially tether molecules together in a chaperone-regulated system. Alternately, sacsin may 
function as a chaperone for a specific client or group of client proteins with the possibility that client 
protein misfolding impacts on Drp1 mediated fission through loss or gain of function. This would be 
partly analogous to common neurodegenerative diseases where both aberrant protein folding and 
disrupted mitochondrial dynamics are features. 
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Materials and Methods 
 
Cell culture and sacsin knockdown 
SH-SY5Y cells were from the American Type Culture Collection and were grown in Dulbecco’s 
Minimum Eagle Medium (DMEM) at a 1:1 ratio with Ham’s F12 medium. Cells were maintained in 
medium supplemented with 10% heat-inactivated foetal bovine serum (FCS) containing 100U ml-1 
penicillin and 100 mg ml-1 streptomycin. ARSACS patient fibroblasts were a gift from Dr Sascha 
Vermeer and colleagues at Radboud University Nijmegen Medical Centre (Nijmegen, 
Netherlands). These cells were collected as part of a project approved by the Medical Ethics 
Committee of the Radboud University (CMO-nr 2014/155). Written informed consent to participate 
in this study was obtained from all patients. Control human dermal fibroblasts were purchased from 
PromoCell (Heidelberg, Germany) or were kindly provided by Dr Tristan McKay (Biomedical 
Sciences, St George’s, University of London), or Dr Sascha Vermeer. Control and ARSACS HDF 
lines used in this work were not closely age or sex matched, but were all between passage 3 and 
8. HDFs were cultured in DMEM supplemented with 10% FBS and 50U/ml penicillin and 50µg ml-1 
streptomycin (final concentration in media 1%). All cells were kept in a constant humidified 
atmosphere of 5% CO2 at 37ºC. Cell culture reagents were from Life Technologies (Paisley, UK). 
To induce mitochondrial fission cells were treated for 1 hour with 20µM CCCP, in their standard 
culture medium. 
 
For sacsin knockdown a combination of three previously validated siRNAs targeting exons 6 
(sense: GGAUGAUCCUCUGAAGGUC), 7 (sense: GCGGCCGAAUUCUAUAAAG) and 9 (sense: 
CGUAAGAUUUCUAGAUGAC) of SACS were used (3, 6). These siRNAs were at a concentration 
of 10nM each and were transfected in combination using Lipofectamine 3000 (ThermoFisher 
Scientific, Paisley, Scotland), according to the manufacturers instructions. A negative control 
siRNA that has no significant sequence similarity to human gene sequences was used as a control 
at a concentration of 30nM. 
 
Microarrays and RT-qPCR  
Total RNA was isolated from SH-SY5Y cells (48 hours post transfection with siRNAs) or from 
HDFs using the RNeasy Mini kit (Qiagen, Hilden, Germany). RNA samples were then reversed 
transcribed using the QuantiTect Reverse Transcription Kit (Qiagen) to give cDNA. Gene 
expression profiling using cDNA from SH-SY5Y or HDFs was then performed using a HumanHT-
12 v4 Expression BeadChip arrays (Illumina, San Diego, USA). All arrays were hybridised at 58 °C 
for 16–20 h, followed by wash and stain procedures according to the Direct Hybridization Assay 
Guide (Illumina). Fluorescent signals were obtained by scanning with iScan System, and data were 
extracted with Gene Expression Module 1.0.6 in GenomeStudio Software 2011.1 (Illumina) with or 
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without background subtraction. Pathway and ontology analysis were performed using DAVID (The 
Database for Annotation, Visualization and Integrated Discovery) v6.7, which enabled functional 
annotation clustering (19). RT-qPCR was performed using the MX3000p QPCR Systems (Agilent, 
Santa Clara, USA). PCR reactions contained 100ng of template cDNA, 200nM of each gene 
specific primer, 5µl of qPCRBIO SyGreen Mix (PCR Biosystems, London, UK) and were made to a 
total volume of 10µl with ultra pure water. Relative gene expression was calculated using the 2(-
Delta Delta C(T)) (∆∆CT) method where GAPDH was used as the reference gene (35). That 
GAPDH transcript levels in sacsin knockdown SH-SY5Y cells were not significantly different from 
controls was confirmed by RT-qPCR using 18S RNA levels for normalisation (not shown). PCR 
conditions and primer sequence for NDUFB3, NDUFB8, NDUFA9, NDUFB9, SDHD, UQCRFS1, 
COX7B, COX17, ATP5J, ATP5J2, SOD2, MAFF, FOSB, FOS, ATF3, SUCLA2, MTCH1, HSPE1 
and GAPDH are available upon request. 
 
Oxygen consumption rate measurement 
Oxygen consumption rate was measured using an XF Extracellular Flux Analyser (Seahorse 
Bioscience, Massachusetts, USA). SH-SY5Y and HDFs were seeded at densities of 50,000 and 
300,000 cells per well respectively. Cells were cultured on Seahorse XF-96 microplates and 
allowed to grow overnight. On the day of metabolic flux analysis, cells were changed to unbuffered 
DMEM (DMEM base medium supplemented with 10 mM glucose, 1 mM sodium pyruvate, 2 mM L-
Glutamine, pH 7.4) and incubated at 37°C in a non-CO2 incubator for 1 h. All medium and injection 
reagents were adjusted to pH 7.4 on the day of assay. Baseline measurements of oxygen 
consumption rate (OCR, measured by oxygen concentration change) and extracellular acidification 
rate (ECAR, measured by pH change) were taken before sequential injection of 
treatments/inhibitors: oligomycin (ATP synthase inhibitor, 4 µM), FCCP (mitochondrial respiration 
uncoupler, 1 µM), and antimycin A (Complex III inhibitor, 1 µM) in conjunction with rotenone 
(Complex I inhibitor, 1 µM). Four measurements over time were collected for each condition with 
10-12 replicates per sample. Data was normalised to protein concentration (measured by Bradford 
assay). 
 
Detection of ROS 
For detection of ROS cells were seeded in 35mm dishes with a glass insert designed for live cell 
imaging (MatTek Corporation, Ashland, USA), They were then stained with MitoSOX Red when 
80% confluent. For staining, MitoSOX Red was diluted to a final concentration of 5mM solution in 
phosphate buffer saline (PBS) containing 100 mM calcium and magnesium (PBS/Ca/Mg). Cells 
were washed once in PBS/Ca/Mg prior to MitoSOX addition and three further times after a 10-
minute incubation (at 37ºC in a 5% CO2 environment) with the dye. For imaging, dishes were 
placed on a 37°C heated stage and Z-stacks were collected using the 40x objective of a Zeiss 
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LSM510 laser scanning confocal microscope (Zeiss, Jena, Germany). Fluorescent intensity was 
measured using the LSM510 Zen software, which allowed for the measurement of fluorescent 
intensity within a selected region of interest. All confocal image acquisition settings were constant 
throughout the experiment, including for comparison between patient and control cells. 
 
Immunofluorescent detection and staining 
Immunofluorescent staining was as described previously (3). Briefly, cells cultured on glass 
coverslips were fixed with 4% formaldehyde for 15 minutes and then permeablised for 5 minutes 
with 0.2% Triton-X 100. Cells were incubated with primary antibodies for 2 hours in 0.02% Triton-
X100, 1% bovine serum albumin and 10% normal goat serum, prior to washing and incubation with 
fluorescently labelled secondary antibodies (Alexa Fluor 488-conjugated goat anti-rabbit or Alexa 
Fluor 543 conjugated goat anti-mouse (ThermoFisher Scientific). Cells were then counterstained 
with DAPI and coverslips mounted for microscopy. Primary antibodies were used at the following 
titres; 1:500 for rabbit polyclonal anti-Tom20 (Santa Cruz Biotechnology); and 1:100 for 
monoclonal anti-Drp1 (BD Transductions, Oxford, UK). For staining of mitochondria with 
MitoTracker (ThermoFisher Scientific) the stock solution was diluted to a concentration of 100nM in 
cell culture media prior to addition to cells for 30 minutes at 37ºC in 5% CO2 atmosphere.  After the 
incubation period, cells were washed twice cell culture media prior to live imaging or fixation. 
Confocal microscopy was performed using a LSM510 with a 63x objective.  
 
Morphometric analyses of mitochondrial networks 
Morphometric analyses of mitochondrial network organisation was performed on live cells as 
described previously (3). For volumetric analyses confocal Z-stacks of MitoTracker stained cells 
were collected and used to generate maximum intensity projections. Surface rendered 3D images 
generated using the Surpass module of the Imaris image analysis software (Imaris 7.6.1 Bitplane, 
Concord, USA) were then used to calculate mitochondrial number and volume. Image acquisition 
settings and thresholding was consistent across datasets.  
 
Quantitative analyses of Drp1 localisation 
The number of Drp1 foci per micrometre of mitochondrial length was determined using the line 
trace function of the LSM510 Zen confocal software. Line trace measured the intensity of channel 
used for detection of mitochondrial and Drp1 fluorescent staining along individual mitochondria. 
The number of Drp1 foci along the measured length of mitochondria was then collated from the 
graphical and tabular output. Drp1 foci intensity and diameter were measured from confocal 
images using a combination of the Surpass module and MeasurementPro modules of Imaris image 
analysis software. The mean intensity and diameter of Drp1 was quantified on randomly chosen 
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mitochondria and in adjacent cytosolic regions in randomly chosen cells from three separate 
experiments. Area selection was blind to experimental status.  
 
Detection of Drp1 complexes 
To study the effect of sacsin knockdown on Drp1 complex formation, SH-SY5Y cells were 
transfected with either SCRM or SACS siRNA, and 48 hours post-transfection cells were subjected 
to chemical cross-linking. The cleavable, homo-bifunctional cross-linker 
dithiobis[succinimidylpropionate] (DSP; Pierce) was added to the cultured cells and incubated for 1 
hour at room temperature. Cross-linking was stopped by addition of Tris (pH 7.5) to a final 
concentration of 20mM. Cells were then lysed and an equal volume of 2x SDS-PAGE sample 
buffer, without the reducing agent 2-Mercaptoethanol (2-ME). Drp1 was detected with monoclonal 
anti-Drp1 at a titre of 1:500. GAPDH was also immunoblotted as a loading control with a rabbit 
anti-GAPDH at a titre of 1:5000  (Abcam). 
 
Mitochondrial turnover 
Tet-On SH-SY5Y cells (a gift from Michael Cheetham, University college London), grown on glass 
coverslips, were co-transfected with pTRE-tight-MitoTimer (21) and control siRNAs or siRNAs 
targeting SACS. 24 hours after transfection cells were transferred to media containing 2µg ml-1 
doxycycline for our hour. After one hour doxycycline was removed and cells washed before being 
returned to normal media. Cells were subsequently fixed and prepared for confocal imaging. This 
was done 24 and 48 hours after the doxycycline pulse. Confocal Z-stacks were collected blind to 
experimental status and levels of mitochondrial MitoTimer fluorescence analysed from maximum 
intensity projections. Image acquisition settings and thresholding was consistent across datasets. 
MitoTimer fluorescent protein has a time-dependent transition from green to red fluorescent 
emission over time (this has previously been shown to take 48 hours in HEK-293 cells (21)). 
Consistent with this, and that we achieved a short period of MitoTimer expression, green 
fluorescence was not at quantifiable levels at 48 hours post the doxacycline treatment in control or 
sacsin knockdown cells. 
 
Statistical analyses 
Statistical significance was determined by a student’s t-Test in the sacsin knockdown dataset and 
ANOVA or Mann-Whitney U tests in the ARSACS patient HDF dataset. 
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Figure Legends 
 
Figure 1. Microarray analyses identify altered expression of genes associated with 
mitochondrial function in cells with reduced levels of sacsin. (A) Schematic summary of 
microarray study design. Two microarray experiments were performed. The first compared gene 
expression in SH-SY5Y cells transfected with siRNAs targeting sacsin (SACS) and scrambled 
(SCRM) control siRNAs. The second experiment compared gene expression in ARSACS patient 
and WT control HDF. Gene ontology analyses were used to identify functional clusters of genes 
that were altered in both experiments. (B) Functional clustering of mitochondrial genes identified 
as having altered expression by microarray analyses in both SACS knockdown SH-SY5Y and 
ARSACS patient HDFs. (C) Fold change in expression of mitochondrial genes identified through 
microarray analyses comparing SH-SY5Y cells transfected with siRNAs targeting sacsin and 
scrambled siRNAs. (D) Fold change in expression of mitochondrial genes identified through 
microarray analyses comparing ARSACS patient and WT control HDFs.  
 
Figure 2. RT-qPCR analyses shows cells with reduced levels of sacsin have alterations in 
levels of oxidative phosphorylation and oxidative stress gene transcripts. Comparison of 
transcript levels of oxidative phosphorylation (A), oxidative stress (B), and mitochondrion 
component (C) genes between SH-SY5Y cells transfected with siRNAs targeting sacsin and 
scrambled siRNAs. RT-qPCR was performed on total RNA extracted from 5 separate knockdown 
SACS experiments. Transcript levels of the genes analysed were normalised to GAPDH levels 
with data shown as mean fold change relative to cells transfected with scrambled siRNA (SCRM). 
Statistical significances determined by t-test are indicated. Comparison of transcript levels of 
oxidative phosphorylation (D), oxidative stress (E), and mitochondrion component (F) genes 
between ARSACS patient and WT control HDFs. RT-qPCR was performed on total RNA extracted 
from 4 ARSACS HDF lines and 5 WT control HDF lines. Transcript levels of the genes analysed 
were normalised to GAPDH levels with data shown as mean fold change relative to WT controls. 
Statistical significances were determined by Mann-Whitney U test. Error bars = SD. * p≤0.05, ** 
p≤0.005, *** p≤0.005. 
 
Figure 3. Bioenergetic function of mitochondria is impaired in sacsin knockdown and 
ARSACS patient cells. (A) Comparison of oxygen consumption rate (OCR) between cells 
transfected with siRNAs targeting sacsin and control siRNAs. (B) Comparison of basal respiration, 
ATP production, proton leak, maximum respiration and spare capacity in cells transfected with 
siRNAs targeting sacsin and control siRNAs, were calculated from the mean of 4 time points (C) 
Comparison of OCR between ARSACS patient and control cell lines. Measurements were made 
under basal conditions and after addition of oligomycin, FCCP and Antimycin A plus rotenone 
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(arrows indicate the time points when drugs were added). (D) Comparison of basal respiration, 
ATP production, proton leak, maximum respiration and spare capacity in ARSACS patient and 
control HDFs, were calculated from the mean of 4 time points. For siRNA knockdown experiments 
n=12 (12 independent transfection for SACS and SCRM siRNAs) and for ARSACS patient cells 
n=4 (4 patient and 4 control HDF lines). Statistical significances were determined by T test or 
Mann-Whitney U test as appropriate. Error bars = SD. * p≤0.05, ** p≤0.005, *** p≤0.005. 
 
Figure 4. Levels of ROS are increased in ARSACS patient HDFs relative to controls. (A) 
Representative images of wild-type control and ARSACS patient HDFs stained the mitochondrial 
superoxide indicator MitoSOX (red). Live cell confocal imaging was used to generate maximum 
intensity projections. Scale bar = 10µm (B) MitoSOX fluorescent intensity was then quantified in 
individual cells from confocal maximum intensity projections (measurements were made in 25 cells 
in each patient and control line with three experimental replicates). Error bars = SEM. * p≤0.05, ** 
p≤0.005, *** p≤0.005. 
 
Figure 5. Localisation of Drp1 to mitochondria is reduced in sacsin knockdown cells. (A) 
HDFs were cotransfected with control scrambled (SCRM) siRNA or siRNA targeting sacsin (SACS) 
and DSRed2-mito (red). After 48 hours cells were treated for 1 hour with 20 CCCP and then 
processed for immunofluorescent detection of Drp1 (green) and counterstained with DAPI (blue) 
for nuclei. Examples of mitochondrial associated Drp1 foci are indicated by arrows. Scale bar = 
10µm (B) The number of Drp1 foci that localised to mitochondria in SCRM and SACS cells with 
and without CCCP treatment were then quantified from confocal Z-stacks. This data was 
expressed as the number of Drp1 foci localised to mitochondria per 1 µm of measured length 
(quantification was performed from at least 6 mitochondria in 60 cells for each treatment, from 
three independent replicates). (C) Panel showing representative micrographs used to quantify the 
diameter (D) and fluorescent intensity (E) of mitochondrial associated and cytosolic localised Drp1 
foci (at least 450 foci were measured from 18 cells, from 3 independent replicates). (F) Immunoblot 
showing high molecular weight Drp1 complexes are reduced in sacsin knockdown cells. SH-SY5Y 
cells were transfected with control scrambled (SCRM) siRNA or siRNA targeting sacsin (SACS). 
After 48 hours cells were treated with the crosslinker DSP and lysed. Total cell lysates were blotted 
under reducing (+2-ME) and non-reducing conditions for Drp1. Levels of sacsin in SCRM and 
SACS cells were assessed by immunoblot for sacsin while GAPDH was used as a loading control. 
Arrow indicates high molecular weight Drp1 species. (G) Densitometry analyses of immunoblots 
was used to quantify the ratio of high molecular weight Drp1 complexes relative to monomeric 
Drp1 (n=5). Statistical significances were determined by T test. Error bars = SEM. * p≤0.05, ** 
p≤0.005, *** p≤0.005. 
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Figure 6. Localisation of Drp1 to mitochondria is reduced in ARSACS patient cells. (A) 
Control and patient HDFs were treated for 1 hour with CCCP and then processed for 
immunofluorescent detection of Tom20 (red) and Drp1 (green). Cells were also counterstained 
with DAPI (blue) to detect nuclei. Representative images are shown for two control lines (WT1 and 
WT2) and each ARSACS patient line used in this study. Examples of mitochondrial associated 
Drp1 foci are indicated by arrows. Scale bar = 10µm. (B) The number of Drp1 foci that localised to 
mitochondria in control and patient HDFs with and without CCCP treatment were then quantified 
from confocal Z-stacks. This data was expressed as the number of Drp1 foci localised to 
mitochondria per 1 µm of measured length (using 4 patient and 4 control lines quantification was 
performed from at least 6 mitochondria in 45 cells for each treatment, from three independent 
replicates). (C-D) Quantification of the diameter (C) and fluorescent intensity (D) of mitochondrial 
associated and cytosolic localised Drp1 foci (at least 500 foci were measured from 18 cells, from 3 
independent replicates). Statistical significances were determined by Mann-Whitney U test. Error 
bars = SEM. * p≤0.05, ** p≤0.005, *** p≤0.005. 
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Supplementary: Figure Legends 
Figure S1. Confirmation of efficient siRNA-mediated knockdown of sacsin. (A) SH-SY5Ys 
were cotransfected with control scrambled (SCRM) siRNA or siRNA targeting sacsin (SACS) and 
DSRed2-mito (red). After 48 hours cells were stained for sacsin (green) and confocal imaging 
performed. The siRNAs were in excess to the DSRed2-mito plasmid in the transfection (molar ratio 
168,000:1), such that we assumed any cell expressing DSRed2-mito would also contain the 
siRNAs. Confocal imaging demonstrated sacsin staining (indicated by arrows) was reduced in 
transfected cells. (B) Cell lysates were also generated from scrambled siRNA and sacsin siRNA 
transfected cells with levels of knockdown assessed by immunoblotting. β-actin used as a loading 
control. (C) Quantitative analyses by densitometry indicated that 48 hours post transfection cellular 
levels of sacsin were reduced by more than 80%. The anti-sacsin used was a commercial antibody 
that binds an unknown peptide between residues 4100 and 4200 of human sacsin.  
 
Figure S2. Phenotype of ARSACS HDF cell lines used in this study. (A) Summary of 
phenotypic characteristics of ARSACS patients who provided HDFs for this study. All patients were 
clinically examined by a neurologist using the Scale for the Assessment and Rating of Ataxia 
(SARA). This is an eight item scale that provides a comprehensive rating of simple ataxia tests 
including the following items: gait, stance, sitting, speech disturbance, finger chase, nose-finger 
test, fast alternating movements and heel-shin slide. All patients showed severe gait spasticity.  All 
patients displayed severe lower limb spasticity except for patient 3 who showed moderate lower 
limb spasticity but with a mild upper limb spasticity that was not seen in the other 3 patients.  They 
all displayed a sensomotor axonal neuropathy on EMG, with a secondary demyelination occurring 
in patient 4. (B) Immunoblot analyses of lysates from four WT control and four ARSACS HDF cell 
lines. Patient numbers correspond with those in the table (A). Lysates were also probed with β-
actin as a loading control. Error bars = SD 
 
Figure S3. Sacsin knockdown HDFs have a hyperfused phenotype. (A) HDFs were 
cotransfected with control scrambled (SCRM) siRNA or siRNA targeting sacsin (SACS) and 
DSRed2-mito (red). Confocal imaging was then performed, with representative images shown. 
Scale bar = 10µm. (B) Incidence of cells containing hyperfused mitochondria was then quantified 
blind to experimental status. (C) Surface rendered 3D images were generated from confocal Z-
stacks of HDF and used to calculate the mean mitochondrial volume per cell in control transfected 
and sacsin knockdown cells. (D) The number of individual mitochondrion was also quantified in 
control transfected and sacsin knockdown cells, after 1 hour treatment with vehicle control or 20µM 
CCCP to induce mitochondrial fission. Statistical significances were determined by T test. Error 
bars = SD.  
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Figure S4. Localisation of Drp1 to mitochondria is reduced in sacsin knockdown SH-SY5Y 
cells. (A) SH-SY5Ys were cotransfected with control scrambled (SCRM) siRNA or siRNA targeting 
sacsin (SACS) and DSRed2-mito (red). After 48 hours cells were treated for 1 hour with CCCP and 
then processed for immunofluorescent detection of Drp1 (green) and counterstained with DAPI 
(blue) for nuclei. Examples of mitochondrial associated Drp1 foci are indicated by arrows. Scale 
bar = 10µm. (B) The number of Drp1 foci that localised to mitochondria in SCRM and SACS cells 
with and without CCCP treatment were then quantified from confocal Z-stacks. This data was 
expressed as the number of Drp1 foci localised to mitochondria per 1 µm of measured length 
(quantification was performed from at 14 cells per treatment, from three independent replicates). 
Statistical significances were determined by T test. Error bars = SEM. ** p≤0.001, *** p≤0.005. (C) 
Levels of Drp1 in SCRM and SACS cells were assessed by immunoblot, while GAPDH was used 
as a loading control. (D) Quantitative analyses by densitometry indicated that 48 hours post 
transfection total cellular levels of Drp1 were not significantly altered in sacsin knockdown cells. (E) 
Representative immunoblot of SH-SY5Y cells transiently transfected with SACS or SCRM siRNA 
and subjected to subcellular fractionation. Total (T) and mitochondrial (M) fractions were 
immunoblotted for Drp1 and Tom20. (F) Densitometric analysis of DRP1 levels in the mitochondrial 
fraction relative to TOM20 suggests a reduction in SACS compared to SCRM siRNA treated cells 
(n = 2). Error bars = SD (in D and F) 
 
Figure S5. Mitochondrial turnover is decreased in sacsin knockdown cells. (A) 
Representative images of SH-SY5Y cells 24 and 48 hours after a pulse of MitoTimer protein 
expression. Tet-On SH-SY5Y were cotransfected with control scrambled (SCRM) siRNA or siRNA 
targeting sacsin (SACS) and pTRE-tight-MitoTimer (red). After 24 hours cells were treated for 1 
hour with doxycycline and then returned to normal media for a further 24 or 48 hours prior to 
fixation and confocal imaging. (B) MitoTimer red fluorescent intensity was then quantified in 
individual cells from confocal maximum intensity projections (data is from a representative 
experiment, where a minimum of 9 cells was imaged per condition). MitoTimer green fluorescence 
was not at quantifiable levels at 48 hours post the doxacycline treatment in control or sacsin 
knockdown cells, consistent with a short period of MitoTimer expression, and is not shown. Error 
bars = SEM. ** p≤0.005. 
 
Figure S6. Mitochondrial network organisation is altered in ARSACS patient HDFS. (A) 
Confocal Z-stacks of live control and patient HDFs stained with MitoTraker were acquired to 
generate maximum intensity projections. Scale bar = 10µm (B) Surface rendered 3D images were 
generated from this data and used to calculate the number of individual mitochondria and their 
volume. This data is shown as the frequency of individual mitochondria for a representative control 
cell line and each patient analysed. (C-D) From these data the average mitochondrial volume per 
 26 
cell (in µm3) was calculated. This is shown for each patient cell line (C) and cumulative for the 4 
patient cells lines analysed (D). Measurements were made in at least 25 cells per line. Error bars = 
SEM. 
 
Figure S7. Localisation of Drp1 to mitochondria is reduced in all ARSACS patient cell lines. 
(A) Control and patient HDFs were treated for 1 hour with CCCP and then processed for 
immunofluorescent detection of mitochondria and Drp1. The number of Drp1 foci that localized to 
mitochondria in control and patient HDFs with and without CCCP treatment were then quantified 
from confocal Z-stacks. This is shown for individual patient cell lines. This data was expressed as 
the number of Drp1 foci localized to mitochondria per 1 µm of measured length (quantification was 
performed from at least 6 mitochondria in 45 cells for each treatment, from three independent 
replicates). Error bars = SEM. *** p≤0.005. 
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Figure S1. Confirmation of efficient siRNA-mediated knockdown of sacsin. (A) SH-SY5Ys 
were cotransfected with control scrambled (SCRM) siRNA or siRNA targeting sacsin (SACS) and 
DSRed2-mito (red). After 48 hours cells were stained for sacsin (green) and confocal imaging 
performed. The siRNAs were in excess to the DSRed2-mito plasmid in the transfection (molar ratio 
168,000:1), such that we assumed any cell expressing DSRed2-mito would also contain the 
siRNAs. Confocal imaging demonstrated sacsin staining (indicated by arrows) was reduced in 
transfected cells. (B) Cell lysates were also generated from scrambled siRNA and sacsin siRNA 
transfected cells with levels of knockdown assessed by immunoblotting. -actin used as a loading 
control. (C) Quantitative analyses by densitometry indicated that 48 hours post transfection cellular 
levels of sacsin were reduced by more than 80%. The anti-sacsin used was a commercial antibody 
that binds an unknown peptide between residues 4100 and 4200 of human sacsin. 
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Figure S2. Phenotype of ARSACS HDF cell lines used in this study. (A) Summary of 
phenotypic characteristics of ARSACS patients who provided HDFs for this study. All patients were 
clinically examined by a neurologist using the Scale for the Assessment and Rating of Ataxia 
(SARA). This is an eight item scale that provides a comprehensive rating of simple ataxia tests 
including the following items: gait, stance, sitting, speech disturbance, finger chase, nose-finger 
test, fast alternating movements and heel-shin slide. All patients showed severe gait spasticity.  All 
patients displayed severe lower limb spasticity except for patient 3 who showed moderate lower 
limb spasticity but with a mild upper limb spasticity that was not seen in the other 3 patients.  They 
all displayed a sensomotor axonal neuropathy on EMG, with a secondary demyelination occurring 
in patient 4. (B) Immunoblot analyses of lysates from four WT control and four ARSACS HDF cell 
lines. Patient numbers correspond with those in the table (A). Lysates were also probed with -
actin as a loading control. Error bars = SD 
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Figure S3. Sacsin knockdown HDFs have a hyperfused phenotype. (A) HDFs were 
cotransfected with control scrambled (SCRM) siRNA or siRNA targeting sacsin (SACS) and 
DSRed2-mito (red). Confocal imaging was then performed, with representative images shown. 
Scale bar = 10 m. (B) Incidence of cells containing hyperfused mitochondria was then quantified 
blind to experimental status. (C) Surface rendered 3D images were generated from confocal Z-
stacks of HDF and used to calculate the mean mitochondrial volume per cell in control transfected 
and sacsin knockdown cells. (D) The number of individual mitochondrion was also quantified in 
control transfected and sacsin knockdown cells, after 1 hour treatment with vehicle control or 20 M 
CCCP to induce mitochondrial fission. Statistical significances were determined by T test. Error 
bars = SD.  
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Figure S4. Localisation of Drp1 to mitochondria is reduced in sacsin knockdown SH-SY5Y 
cells. (A) SH-SY5Ys were cotransfected with control scrambled (SCRM) siRNA or siRNA targeting 
sacsin (SACS) and DSRed2-mito (red). After 48 hours cells were treated for 1 hour with CCCP and 
then processed for immunofluorescent detection of Drp1 (green) and counterstained with DAPI 
(blue) for nuclei. Examples of mitochondrial associated Drp1 foci are indicated by arrows. Scale 
bar = 10 m. (B) The number of Drp1 foci that localised to mitochondria in SCRM and SACS cells 
with and without CCCP treatment were then quantified from confocal Z-stacks. This data was 
expressed as the number of Drp1 foci localised to mitochondria per 1 m of measured length 
(quantification was performed from at 14 cells per treatment, from three independent replicates). 
Statistical significances were determined by T test. Error bars = SEM. ** p 0.001, *** p 0.005. (C) 
Levels of Drp1 in SCRM and SACS cells were assessed by immunoblot, while GAPDH was used 
as a loading control. (D) Quantitative analyses by densitometry indicated that 48 hours post 
transfection total cellular levels of Drp1 were not significantly altered in sacsin knockdown cells. (E) 
Representative immunoblot of SH-SY5Y cells transiently transfected with SACS or SCRM siRNA 
and subjected to subcellular fractionation. Total (T) and mitochondrial (M) fractions were 
immunoblotted for Drp1 and TOM20. (F) Densitometric analysis of DRP1 levels in the 
mitochondrial fraction relative to TOM20 suggests a reduction in SACS compared to SCRM siRNA 
treated cells (n = 2). Error bars = SD (in D and F) 
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Figure S5. Mitochondrial turnover is decreased in sacsin knockdown cells. (A) 
Representative images of SH-SY5Y cells 24 and 48 hours after a pulse of MitoTimer protein 
expression. Tet-On SH-SY5Y were cotransfected with control scrambled (SCRM) siRNA or siRNA 
targeting sacsin (SACS) and pTRE-tight-MitoTimer (red). After 24 hours cells were treated for 1 
hour with doxycycline and then returned to normal media for a further 24 or 48 hours prior to 
fixation and confocal imaging. (B) MitoTimer red fluorescent intensity was then quantified in 
individual cells from confocal maximum intensity projections (data is from a representative 
experiment, where a minimum of 9 cells was imaged per condition). MitoTimer green fluorescence 
was not at quantifiable levels at 48 hours post the doxacycline treatment in control or sacsin 
knockdown cells, consistent with a short period of MitoTimer expression, and is not shown. Error 
bars = SEM. ** p 0.005. 
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Figure S6. Mitochondrial network organisation is altered in ARSACS patient HDFS. (A) 
Confocal Z-stacks of live control and patient HDFs stained with MitoTraker were acquired to 
generate maximum intensity projections. Scale bar = 10 m (B) Surface rendered 3D images were 
generated from this data and used to calculate the number of individual mitochondria and their 
volume. This is shown as the frequency of individual mitochondria for a representative control cell 
line and each patient analysed. (C-D) From these data the average mitochondrial volume per cell 
(in m3) was calculated. This is shown for each patient cell line (C) and cumulative for the 4 patient 
cells lines analysed (D). Measurements were made in at least 25 cells per line. Error bars = SEM. 
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Figure S7. Localisation of Drp1 to mitochondria is reduced in all ARSACS patient cell lines. 
(A) Control and patient HDFs were treated for 1 hour with CCCP and then processed for 
immunofluorescent detection of mitochondria and Drp1. The number of Drp1 foci that localized to 
mitochondria in control and patient HDFs with and without CCCP treatment were then quantified 
from confocal Z-stacks. This is shown for individual patient cell lines. This data was expressed as 
the number of Drp1 foci localized to mitochondria per 1 m of measured length (quantification was 
performed from at least 6 mitochondria in 45 cells for each treatment, from three independent 
replicates). Error bars = SEM. *** p 0.005. 
